GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $7.97 Average Target Price from Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been given a consensus recommendation of “Hold” by the fourteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $7.97.

Several research analysts have issued reports on the stock. DA Davidson upgraded shares of GoodRx from a “neutral” rating to a “buy” rating and set a $9.50 price target on the stock in a research report on Thursday, August 10th. Morgan Stanley lowered their price objective on shares of GoodRx from $8.00 to $5.50 and set an “equal weight” rating on the stock in a research report on Friday, November 10th. Citigroup lifted their price objective on shares of GoodRx from $7.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday, August 10th. JPMorgan Chase & Co. lowered their price objective on shares of GoodRx from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Credit Suisse Group boosted their price target on shares of GoodRx from $7.00 to $8.00 and gave the company a “neutral” rating in a report on Thursday, August 10th.

GoodRx Trading Up 10.1 %

GoodRx stock opened at $5.76 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 8.23 and a current ratio of 8.23. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of 144.00, a price-to-earnings-growth ratio of 5.41 and a beta of 1.17. GoodRx has a 1 year low of $4.14 and a 1 year high of $9.37. The firm’s 50 day moving average price is $5.39 and its two-hundred day moving average price is $5.92.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Thursday, November 9th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. The firm had revenue of $180.00 million for the quarter, compared to analyst estimates of $188.52 million. GoodRx had a net margin of 2.04% and a return on equity of 2.25%. The firm’s quarterly revenue was down 3.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.07 earnings per share. On average, research analysts predict that GoodRx will post 0.08 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Scott Wagner bought 104,079 shares of the business’s stock in a transaction on Thursday, November 16th. The stock was purchased at an average price of $5.16 per share, with a total value of $537,047.64. Following the transaction, the insider now directly owns 104,079 shares in the company, valued at $537,047.64. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 1.37% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Moneta Group Investment Advisors LLC raised its position in shares of GoodRx by 12.8% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 17,148 shares of the company’s stock valued at $80,000 after buying an additional 1,945 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of GoodRx by 12.5% during the third quarter. Dimensional Fund Advisors LP now owns 19,383 shares of the company’s stock valued at $91,000 after buying an additional 2,153 shares during the last quarter. Carmel Capital Partners LLC raised its position in shares of GoodRx by 7.2% during the second quarter. Carmel Capital Partners LLC now owns 33,365 shares of the company’s stock valued at $184,000 after buying an additional 2,242 shares during the last quarter. Raymond James & Associates raised its position in shares of GoodRx by 24.0% during the first quarter. Raymond James & Associates now owns 13,806 shares of the company’s stock valued at $267,000 after buying an additional 2,675 shares during the last quarter. Finally, Harbor Capital Advisors Inc. raised its position in shares of GoodRx by 22.7% during the third quarter. Harbor Capital Advisors Inc. now owns 14,995 shares of the company’s stock valued at $84,000 after buying an additional 2,771 shares during the last quarter. Institutional investors and hedge funds own 33.63% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.